| 前收市價 | 11.30 |
| 開市 | 12.11 |
| 買盤 | 0.00 |
| 賣出價 | 5.00 |
| 拍板 | 165.00 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 11.30 - 12.11 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 24 |
BenzingaFDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Tuesday, Ascendis Pharma A/S (NASDAQ:ASND) announced that the FDA extended the review date for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism. Hypoparathyroidism is an uncommon condition in which the body produces abnormally low levels of parathyroid hormone (PTH). The low production of PTH in hypoparathyroidism leads to abnormally low calcium levels in the blood and an increase of phosphorus in the blood. The agency said the information Ascendis Pharma submitted in respon
ZacksFDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
- Reuters
UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy
The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday. U.S.-listed shares of the company were down 6.6% in late afternoon trading. The health regulator notified that data submitted for the ongoing review of the therapy, called TransCon PTH, constituted "a major amendment" to the company's application seeking market approval.
